Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer.
The company works with a number of highly recognised big pharma companies to create antibodies at all stage of the development process.
Genmab’s lead marketed antibody product is Arzerra®, a therapeutic for certain lymphocytic leukaemia indications. Genmab also has a number of pre-clinical innovations in the pipeline and two major antibody technologies Duobody® and Hexabody®. Duobody is a technology platform that discovers, develops and produces bispecific antibodies intended for the treatment of cancer, autoimmune, infectious and central nervous system diseases. Whereas, Hexabody® is a technology platform that specialises in the production of effector function enhanced antibodies that are created by inducing the antibody hexamer formation. The Hexabody platform can be directed to any disease antigen or target and can be combined with the Duobody® platform.
Genmab was set up fairly recently in 1999 in Copenhagen and a year later it filed for an IPO in which it raised $1.56billion, a figure that became a European Biotech record. The success continued from there on in as the company signed its first major antibody partnership with Roche. Over the next ten years Genmab’s in house technologies became the focus of many of the partnerships as key collaborations took place with Novartis, Janssen and Kyowa Hakko Kirin. Today it houses its R&D facilities in the Netherlands and its administrative functions over in the USA.
Genmab revolves its work around three core values – focusing on core competencies, turning science into medicine and building a profitable and successful biotechnology company. The other main strategy for the company is partnering….
Reliant on Partnering
Genmab’s success to date is largely dependent on partnering, ever since it first established back in 1999, it very quickly went onto pen its first official agreement with biotech giants Roche. Partnerships have been formed with the following companies for both its products and technologies.
Antibody technology partners
- Seattle Genetics
- Kyowa Hakko Kirin
- Eli Lilly
- Agenus Inc
Antibody product partners
- Amgen Inc
- Janssen Biotech
- Cormorant Pharmaceuticals
- ADC Therapeutics
These days Genmab is actively seeking partnerships with various companies who are interested in both in-licensing and out-licensing. It is firstly interested in hearing from companies who wish to in-license its products and technologies and on the opposite side any companies who have early stage antibody candidates who wish to develop them with or out-license them to Genmab. Genmab will consider any disease areas where the use of antibody-based therapies may be useful.
Finally, Genmab is also happy to offer its R&D capabilities out to companies to help them identify new antibody candidates that may be then developed to a point where they can be taken on by bigger or more experienced pharmaceutical partners
Genmab is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Other events with Genmab’s presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Genmab in person visit Current Partnering’s Event calendar.
Contacting Genmab for partnering
Genmab can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with the Genmab business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Genmab website has details for contacting the company.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Genmab business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Genmab Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on Genmab website for potential partnering opportunities and general contact names.
Genmab partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Report: Partnering Agreements with Genmab 2009-2014
No M&A activity for Genmab
Available reports from Current Partnering
Report: Partnering Agreements with Genmab 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Genmab
Read: more on Genmab company profile, recent partnering, M&A and financing news and articles
Report:Finding Biopharma Licensing and Collaboration Partners
View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value
View: CP Insight’s M&A Scorecard – view top life science M&A deals by value
View: CP Insight’s Deal Metrics – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk